Triggering of Follicular Maturation

Phase 3

Completed

• Conditions: Increase Pregnancy Rate
• Interventions: Drug: Recombinant Human Chorionic Gonadotrophin; Drug: human chorionic gonadotrophin + gonadotrophin releasing hormone agonist

• Registration Number: NCT02916173
• Lead Sponsor: Assiut University

Brief Summary

The follicular phase of the menstrual cycle involves the hourly release of gonadotropin-releasing hormone, which binds to receptors on the gonadotropes. This results in the secretion of follicle stimulating hormone and luteinizing hormone in hourly pulses that regulate follicular growth. At midcycle, rapidly rising estradiol from the dominant follicle and a small rise in progesterone lead to a gonadotrophic surge. An increase in the amplitude of Luteinizing hormone and Follicle stimulating hormone pulses initiates oocyte maturity and triggers ovulation approximately

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-09-25
• Study First Submitted QC: 2016-09-25
• Study First Posted: 2016-09-27
• Study Start: 2016-11
• Primary Completion: 2018-10
• Study Completion: 2019-02
• Status Verified: 2019-03
• Last Update Submitted: 2019-03-18
• Last Update Posted: 2019-03-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 160

Inclusion Criteria

1. Infertile couples wishing to do intracytoplasmic injection trial .
2. first intracytoplasmic injection trial
3. Body mass index:18-30.

5-Antral follicular count: more than 5 follicles in one ovary 6-normal, mild or moderate male factor infertility. 7- Antimullerian hormone >1 ng/ml

Exclusion Criteria

1. Azoospermic male.
2. Body mass index more than 29.
3. Patients with endometriosis .
4. Antimullerian hormone < 1 ng/ml

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Human chorionic gonadotrophin group	Recombinant Human Chorionic Gonadotrophin	Patients will receive Human chorionic gonadotrohpin injection 5000 unit
Human chorionic gonadotrophin + agonist group	human chorionic gonadotrophin + gonadotrophin releasing hormone agonist	patients will receive both Human chorionic gonadotrophin (2500 unit) and gonadotrophin releasing hormone agonist 1mg leuprolide acetate

Primary Outcome Measures

Name	Time	Method
Number of M II oocytes in both groups	24 hours

Secondary Outcome Measures

Name	Time	Method
Fertilization rate in each group	3 days
Clinical pregnancy rate in each group	15 days

Trial Locations

Locations (1)

Ahmed Abbas; 🇪🇬 Assiut, Cairo, Egypt